Profit Lung Fights Party (Pill) Joint TKI Treatment Ⅲ Type A-phase Ⅳ EGFR Mutations In Non-small Cell Lung Cancer Were Retrospectively Studied

Research PurposeTo Ⅲ a-Ⅳ stage non-small cell lung cancer(non-small cell lung cancer,NSCLC)EGFR gene 19 or 21 locus mutation and at the same time to accept the first generation ofEGFR TKIsand traditional Chinese medicine treatment as the research object,observe the lung fights party(pill)the long-term curative effect of this kind of patients,and profit lung fights(pill)joint EGFR-TKIs raised effect attenuated the effect,and analyze the influence the prognosis of patients survive several relevant index,evaluation of traditional Chinese medicine combined EGFR TKIs-efficacy and safety of the treatment of advanced NSCLC.Objects and methodsThis research for the single arm,single-center retrospective study,for the 2010-9-1-2010-9-1 in the center of the first affiliated hospital of guangzhou university of TCM tumor diagnosed Ⅲ type a-phase Ⅳ EGFR mutations in non-small cell lung cancer cases,a total of 90 cases were analyzed,and observe the patient’s progression-free surial(PFS)and overall survival(OS),skin rashes,diarrhea incidence of adverse reactions and the degree of improvement,such as liver and kidney function change,etc.,and select the adjustment possible confounding factors,introducing multivariate regression model,The effect of traditional Chinese medicine on the prognosis of egfr-tkis was analyzed.Rresults:(1)as of the end of the study period(10 February 2018),90 patients were enrolled in the group.According to 43 cases of PFS,there were 86 cases of OS truncation.PFS was 443.7 + 362.3 days,median of 354 days;The OS was 638.3+ 418.2 days and the median was 512 days.(2)according to the multipleregression analysis,the adjustment of gender,age,treatment,including taking TKI Yi Rui sand,tarceva,kay beauty,such as the baseline situation after the confounding factors,can be found after the occurrence of disease(PD),before the progress of Chinese herbal time(month)HR = 0.888,95% CI(0.831,0.831),P = 0.0006,shows progress before taking time to protect Chinese medicine,1 months per time taking Chinese traditional medicine,11.2%can reduce the risk of disease progression.(3)the threshold effect analysis results suggest that if in a straight line fitting data,the result is taking Chinese traditional medicine every day,increase the number of days with a5.8% drop in risk,95% ci(0.908,0.908),P = 0.0012;If using the two model fitting the data,find out the best point for 376 days,days of the medicine in the 376 days ago,taking Chinese traditional medicine every day,increase the number of days with a 2.2% drop in risk,95% ci(0.967,0.967),P = 0.0001).(4)EGFR TKIs adverse events related to the incidence of rash(84.259%),rash severity in light,medium and heavy respectively 24.719%,38.202%,21.348%of the total number of rash occurs,the rash treatment results in no better and better,the cure rate was 16.854%,16.854%,7.865%,P values were greater than 0.05,there were no statistical significance.The incidence of diarrhea was 65.556%,and the severity of diarrhea was mild,moderate and heavy,respectively,accounting for 50.000%,34.444% and 6.667% of the total number of diarrhea cases.The results of diarrhea treatment showed no improvement,the good turnover rate was 37.778%,62.222%,and the P value was greater than0.05,which was not statistically significant.(5)in the safety analysis,the AST in the low,middle and high groups in the three groups of Chinese traditional Chinese medicine(TCM)time was 19.3,plus or minus 6.9,0.3,plus or minus 13.3,and 25.2,plus or minus 15.4.ALT is 15.5 + + 7.3,8.8 + + 15.9,19.9 + 11.2;CREA is 72.5 plus or minus 18.1,87.6,plus or minus 16.0,77.2+ or 45.1.P value was greater than 0.05,no statistical significance.ConclusionFor Ⅲ type a-phase Ⅳ EGFR mutations in NSCLC treated with EGFR TKIs-while cooperate with profit lung fights party(pills)of traditional Chinese medicine treatment,can prolong the pFS;Taking Chinese traditional medicine for Ⅲ a-phase Ⅳ EGFR gene mutation type the prognosis of NSCLC protection factor,taking Chinese traditional medicine can reduce the risk of disease progression.Therefore,the collaborative EGFR TKIs-have a synergistic effect of Chinese medicine,phase should be as Ⅲ a-Ⅳ EGFR gene mutation type one of the important treatment of NSCLC.